Open Access Helper

OpenAlex Citation Counts

OpenAlex Citations Logo

OpenAlex is a bibliographic catalogue of scientific papers, authors and institutions accessible in open access mode, named after the Library of Alexandria. It's citation coverage is excellent and I hope you will find utility in this listing of citing articles!

If you click the article title, you'll navigate to the article, as listed in CrossRef. If you click the Open Access links, you'll navigate to the "best Open Access location". Clicking the citation count will open this listing for that article. Lastly at the bottom of the page, you'll find basic pagination options.

Requested Article:

A Case of Prolonged Mania, Psychosis, and Severe Depression After Psilocybin Use: Implications of Increased Psychedelic Drug Availability
Gregory Barber, Charles B. Nemeroff, Steven Siegel
American Journal of Psychiatry (2022) Vol. 179, Iss. 12, pp. 892-896
Closed Access | Times Cited: 45

Showing 1-25 of 45 citing articles:

Naturalistic psilocybin use is associated with persisting improvements in mental health and wellbeing: results from a prospective, longitudinal survey
Sandeep M. Nayak, Hillary Jackson, Nathan D. Sepeda, et al.
Frontiers in Psychiatry (2023) Vol. 14
Open Access | Times Cited: 44
Case analysis of long-term negative psychological responses to psychedelics
Rebecka Bremler, Nancy Katati, Parvinder Shergill, et al.
Scientific Reports (2023) Vol. 13, Iss. 1
Open Access | Times Cited: 44
Psychiatric risks for worsened mental health after psychedelic use
Alessia Marrocu, Hannes Kettner, Brandon Weiss, et al.
Journal of Psychopharmacology (2024) Vol. 38, Iss. 3, pp. 225-235
Open Access | Times Cited: 17
A framework for assessment of adverse events occurring in psychedelic-assisted therapies
Roman Palitsky, Deanna M. Kaplan, John Perna, et al.
Journal of Psychopharmacology (2024) Vol. 38, Iss. 8, pp. 690-700
Closed Access | Times Cited: 12
Longitudinal associations between psychedelic use and psychotic symptoms in the United States and the United Kingdom
Ludwig Honk, Cecilia U. D. Stenfors, Simon B. Goldberg, et al.
Journal of Affective Disorders (2024) Vol. 351, pp. 194-201
Closed Access | Times Cited: 9
Psychedelics in Psychiatry: Oh, What A Trip!
Gregory A. Fonzo, Charles B. Nemeroff, Ned H. Kalin
American Journal of Psychiatry (2025) Vol. 182, Iss. 1, pp. 1-5
Closed Access | Times Cited: 1
Primum Non Nocere: The Onus to Characterize the Potential Harms of Psychedelic Treatment
Sharmin Ghaznavi, Jeremy N. Ruskin, Stephen J. Haggerty, et al.
American Journal of Psychiatry (2025) Vol. 182, Iss. 1, pp. 47-53
Closed Access | Times Cited: 1
Healing, Harms, and Humility: Expanding the Scope of Psychedelic-Assisted Psychotherapy Research
Kelley C. O’Donnell, Jim Grigsby, Charles S. Grob
American Journal of Psychiatry (2025) Vol. 182, Iss. 1, pp. 13-16
Closed Access | Times Cited: 1
Psilocybin: From Psychiatric Pariah to Perceived Panacea
Gregory A. Fonzo, Aaron Wolfgang, Bryan Barksdale, et al.
American Journal of Psychiatry (2025) Vol. 182, Iss. 1, pp. 54-78
Closed Access | Times Cited: 1
Prolonged adverse effects from repeated psilocybin use in an underground psychedelic therapy training program: a case report
John Perna, Justin Trop, Roman Palitsky, et al.
BMC Psychiatry (2025) Vol. 25, Iss. 1
Open Access | Times Cited: 1
A Systematic Review of Reporting Practices in Psychedelic Clinical Trials: Psychological Support, Therapy, and Psychosocial Interventions
Bill Brennan, Alex R. Kelman, Alexander B. Belser
Psychedelic Medicine (2023) Vol. 1, Iss. 4, pp. 218-229
Open Access | Times Cited: 21
Co-use of MDMA with psilocybin/LSD may buffer against challenging experiences and enhance positive experiences
Richard J. Zeifman, Hannes Kettner, Broc A. Pagni, et al.
Scientific Reports (2023) Vol. 13, Iss. 1
Open Access | Times Cited: 18
Informed Consent to Psychedelic Treatment—A Work in Progress
Paul S. Appelbaum
JAMA Psychiatry (2024) Vol. 81, Iss. 6, pp. 543-543
Closed Access | Times Cited: 5
A prospective ecological momentary assessment study of an ayahuasca retreat: exploring the salutary impact of acute psychedelic experiences on subacute affect and mindfulness skills in daily life
Sharon R. Sznitman, Yoel A. Behar, Sheila Daniela Dicker‐Oren, et al.
Psychopharmacology (2025)
Open Access
Serotonergic psychedelics as potential therapeutics for post-COVID-19 syndrome (or Long COVID): A comprehensive review
Zhen Xuen Brandon Low, Shin Jie Yong, Hayam A Alrasheed, et al.
Progress in Neuro-Psychopharmacology and Biological Psychiatry (2025), pp. 111279-111279
Closed Access
Psychedelics for Moral Bioenhancement in Healthy Individuals—A Violation of the Non-Maleficence Principle?
Bor Luen Tang
Psychoactives (2025) Vol. 4, Iss. 1, pp. 5-5
Open Access
Longitudinal associations of naturalistic psychedelic use with psychotic and manic symptoms
Otto Simonsson, Simon B. Goldberg, Walter Osika, et al.
Psychological Medicine (2025) Vol. 55
Closed Access
Exploring psilocybin’s role in mental health and palliative medicine: a path to improved well-being
Maria-Alejandra Umbacia, Marta León, Jose-Manuel Quintero, et al.
Expert Opinion on Emerging Drugs (2025)
Closed Access
Psilocybin therapy for mood dysfunction in Parkinson’s disease: an open-label pilot trial
Ellen Bradley, Kimberly Sakai, Gisele Fernandes‐Osterhold, et al.
Neuropsychopharmacology (2025)
Open Access
Psilocybin in Palliative Care: An Update
Emily Whinkin, Moira Opalka, Conor Watters, et al.
Current Geriatrics Reports (2023) Vol. 12, Iss. 2, pp. 50-59
Open Access | Times Cited: 12
Focusing on the negative: cases of long-term negative psychological responses to psychedelics
Rebecka Bremler, Nancy Katati, Parvinder Shergill, et al.
(2023)
Open Access | Times Cited: 8
Psilocybin as a lead candidate molecule in preclinical therapeutic studies of psychiatric disorders: A systematic review
James J Gattuso, Carey Wilson, Anthony J. Hannan, et al.
Journal of Neurochemistry (2023)
Open Access | Times Cited: 8
A Framework for Assessment of Adverse Events Occurring in Psychedelic Assisted Therapies
Roman Palitsky, Deanna M. Kaplan, John Perna, et al.
(2024)
Open Access | Times Cited: 2
Minorities’ Diminished Psychedelic Returns: Gender, Perceived Stigma, and Distress
Sean M. Viña
Psychoactives (2024) Vol. 3, Iss. 2, pp. 303-317
Open Access | Times Cited: 2
The phenomenology of psilocybin’s experience mediates subsequent persistent psychological effects independently of sex, previous experience or setting
Tereza Klučková, M. Nikolič, Filip Tylš, et al.
medRxiv (Cold Spring Harbor Laboratory) (2024)
Open Access | Times Cited: 2
Page 1 - Next Page

Scroll to top